-
Product Insights
Social Anxiety Disorder (SAD/Social Phobia) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Social Anxiety Disorder (SAD/Social Phobia) - Global Clinical Trials Review, 2026" provides an overview of Social Anxiety Disorder (SAD/Social Phobia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Social Anxiety Disorder (SAD/Social Phobia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Spondyloarthritis (Spondyloarthropathy) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Spondyloarthritis (Spondyloarthropathy) - Global Clinical Trials Review, 2026" provides an overview of Spondyloarthritis (Spondyloarthropathy) Clinical trials scenario. This report provides top line data relating to the clinical trials on Spondyloarthritis (Spondyloarthropathy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Muscle Invasive Bladder Cancer (MIBC) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Muscle Invasive Bladder Cancer (MIBC) - Global Clinical Trials Review, 2026" provides an overview of Muscle Invasive Bladder Cancer (MIBC) Clinical trials scenario. This report provides top line data relating to the clinical trials on Muscle Invasive Bladder Cancer (MIBC). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2026" provides an overview of Hemophilia A (Factor VIII Deficiency) Clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia A (Factor VIII Deficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Endometriosis - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Endometriosis - Global Clinical Trials Review, 2026" provides an overview of Endometriosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Endometriosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Chronic Lymphocytic Leukemia (CLL) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Chronic Lymphocytic Leukemia (CLL) - Global Clinical Trials Review, 2026" provides an overview of Chronic Lymphocytic Leukemia (CLL) Clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Diffuse Large B-Cell Lymphoma - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Diffuse Large B-Cell Lymphoma - Global Clinical Trials Review, 2026" provides an overview of Diffuse Large B-Cell Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Primary CNS Lymphoma (PCNSL): Market View, Current and Future Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Primary CNS Lymphoma Therapeutics._x000D_ _x000D_ • In 2024 and 2029, Urban China is anticipated to have the highest number of diagnosed prevalent cases of PCNSL, representing a large proportion of global cases. _x000D_ • Currently, PCNSL treatment relies mostly on off-label agents, and the Bruton's tyrosine kinase (BTK) inhibitors currently available to treat refractory/relapsed (r/r) PCNSL cases._x000D_ • The PCNSL pipeline holds 43 molecules, with no...
-
Sector Analysis
Fibromyalgia: Market View, Current and Future Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Fibromyalgia Therapeutics._x000D_ _x000D_ • In 2024 and 2029, India is anticipated to have the highest number of diagnosed prevalent cases of fibromyalgia, representing a large portion of global cases._x000D_ • Currently, the fibromyalgia treatment landscape has a limited number of approved drugs and is saturated with generics._x000D_ • Fibromyalgia’s pipeline is relatively thin, skewed toward Phase I–II investigational assets with no presence of late-stage molecules._x000D_ •...
-
Sector Analysis
Chemotherapy-Induced Peripheral Neuropathy (CIPN): Market View, Current and Future Competitive Landscape
CIPN Market Forecast, Clinical Trial Activity, and Competitive Intelligence GlobalData’s Chemotherapy-Induced Peripheral Neuropathy (CIPN) report delivers a data-driven overview of the current and future competitive landscape within the CIPN therapeutics market. The report highlights key trends across epidemiology, pipeline development, clinical trials, pricing and reimbursement, commercial activity, and future market catalysts. In addition, it provides insight into marketed therapies, emerging treatment approaches, and competitive positioning across the global market. China is anticipated to account for the highest number of diagnosed...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.